Skip to main content
OLMA logo

OLMA · Olema Oncology, Inc.

Track OLMA — free
$7.02 -0.13 (-1.82%) At close · Nov 20
Market Cap
$615.00M
Shares
87.61M
Volume · Nov 20 1.26M Avg daily vol (3M) 1.27M

Price & Indicators

 

Key stats

Close
$7.02
Fri 20 Nov
Open
$7.01
Fri 20 Nov
Average volume, 30 days
1.5M
shares a session
Short interest
17.1M
19.5% of shares · 11.9 days to cover
Day range
$6.88$7.36
Open $7.01 Close $7.02
52-week closing range
$6.41$35.83
Close $7.02 80.4% under the high
Short volume, last session
67%
Last earnings
May 26, 2026
Latest filing
10-Q · Nov 10
Price history
Nov 2020 to Nov 2026

Up next

May 25, 2027 Est · unconfirmed · in 26 wks

Latest documents

2026
Nov 18
Investor event
Palizestrant OPERO1 trial reads out in Q1

The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints.

4 source passages
OPERO1 is a monotherapy trial in the second, third-line setting, and that reads out in Q1. So in our phase two study, we saw about 7.3 months median PFS in the ESR1 mutant, 5.5 months in the ESR1 wild type. To assess these two patient populations as individual endpoints, so ESR1, PFS and ESR1 mutant, and PFS and ESR1 wild type. The lead is palizestrant. Open the document at this passage
Nov 12
Current report 8-K
Company changes name and relocates principal offices

Olema Oncology, Inc. changed its name from Olema Pharmaceuticals, Inc. effective November 12, 2026. It also relocated its principal executive offices to 365 Oyster Point Blvd., Suite 400, South San Francisco, California 94080.

Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure, Other events Read from the first part of this long document
2 source passages
On November 12, 2026, Olema Oncology, Inc. (formerly known as Olema Pharmaceuticals, Inc.) (the “Company”) filed its Eighth Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware to change the Company's corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” (the “Name Change”). The Restated Certificate became effective at 4:01 p.m., Eastern Time, on November 12, 2026. Effective November 12, 2026, the Company relocated its principal executive offices from 780 Brannan Street, San Francisco, CA 94103 to 365 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080. Open the document at this passage
Nov 11
Investor event
Opera 01 readout slated for Q1 amid strong Opera 2 enrollment

Olima Oncology expects an Opera 01 readout in Q1, said Opera 2 is enrolling “extremely robustly,” and reported $414 million cash, with a possible mid-year 2028 launch.

5 source passages
Here we have Olima Oncology CEO, Sean. obviously in Q1 for OPRO one, the second line, second, third line study, we will have that readout. Opera 2, which is a first-line study with Kiskali, is enrolling extremely robustly. It does depend upon the readout, as you said, of course, of Opera 01. So those launch preparations are underway. earlier this week, did our Q2, $414 million cash at the end. We assume that we're going to be able to launch in 2028, maybe mid-year. Open the document at this passage
Nov 10
Investor event
Phase III topline expected in Q1 of next year

Olema expects Phase III topline results in Q1 of next year, including ESR-1 mutant and ESR-1 wild type subsets; cash on hand of about $414 million provides runway into 2028.

5 source passages
That compound is in two Phase III trials right now. And that trial reads out in... In Q1 of next year this is a very important piece of information for Olima specifically in the ESR-1 mutant and the ESR-1 wild type subsets Our cash on hand is about $414 million. That runway takes us nicely into 2028. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Palazestrant OPERA-01 top-line results expected in 2027

Olema reported a $189.9 million net loss for the nine months ended September 30, 2026. Palazestrant’s Phase 3 OPERA-01 top-line results are expected in the first quarter of 2027, followed by an NDA submission in 2027.

Net loss $73.6M Diluted EPS -$0.73
Read from the MD&A section
2 source passages
Our net losses were $189.9 million and $116.4 million for the nine months ended September 30, 2026 and 2025, respectively. In November 2023, we initiated OPERA-01, our pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC. We have completed enrollment and anticipate top-line results for this trial in the first quarter of 2027, expect to submit the new drug application (NDA) in 2027, and, if successful, anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch in 2028. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$235.95M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$410.77M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.9%
Year over year · more shares
Price change (1Y)
-68.1%
Trailing year
Short interest
19.5%
Latest settlement · 11.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −10%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +10%
trailing
6-month return −34%
trailing
YTD return −72%
this year
Relative strength −25%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $8 › 200d $13 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.55% of shares out · ▲ +9.2% MoM · 11.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
182 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
EPS growth +15%
Y/Y
Free cash flow $-146.9M
Balance sheet $45.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −82%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $13 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.55% of shares out · ▲ +9.2% MoM · 11.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
182 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6 Now $7 · 2% Range high $36
vs 200-day avg -44% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $413.8M September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OLMA
Olema Oncology, Inc.
this stock
$615.00M -71.9% — — 19.5%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
182
% held
116.6%
Net QoQ
+222.0K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
215
View
Short & Settlement
Short Interest Rising
Shares short
17.1M
Days to cover
11.9d
Change
+1.4M sh
View
Short Volume
Short vol %
67%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
400
Value
$3.2K
As of
Oct 7, 2026
View
Off-Exchange
Off-exchange %
46.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-162.5M
EPS diluted
$-1.87
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
27

The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints.

View
Proposed Sales
Value
$146.4K
Shares
12.5K
Filed
Jul 24, 2026
View
Exempt Offerings
Offering
$250.0M
Filed
Dec 12, 2024
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 30, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Olema Oncology Presents Preclinic…
Published
Nov 18, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
OLMA -7.1% +9.5% -34.3% +0.3% -71.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +1.4% +18.8% -25.2% +9.0% -73.1%
Key facts CIK 1750284 CUSIP 68062P106 13F (30d) 188 filings 170 filers Visit website Investor relations